Limits...
In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus

Analgesimeter test: histogram of the % variation of latency of paw-withdrawal recorded in analgesimeter tests 2 (a) and 3 (b) with respect to the mean latency recorded during the first test, in the right and left paw in animals treated with OIL (white), BCP (light gray), and BCP+DHA (dark gray). Values are means ± SEM. *P < 0.01 versus BCP.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4109702&req=5

fig6: Analgesimeter test: histogram of the % variation of latency of paw-withdrawal recorded in analgesimeter tests 2 (a) and 3 (b) with respect to the mean latency recorded during the first test, in the right and left paw in animals treated with OIL (white), BCP (light gray), and BCP+DHA (dark gray). Values are means ± SEM. *P < 0.01 versus BCP.

Mentions: This test was carried out to evaluate the effect of one and two weeks of BCP and BCP+DHA treatment on the mechanical paw-withdrawal threshold with respect to basal conditions (Analg 1). One-way ANOVA applied to the percentage of variation of latency recorded during the second and third tests with respect to the first one revealed different effects of the treatments, while BCP alone always resulted in higher values, that is, analgesia, BCP+DHA tended to produce lower (hyperalgesic) levels. In particular, there was a significant effect of treatment during the second test (Analg 2) for the right (treated) paw (F2,17 = 4.25; P < 0.03) due to the significant difference between the BCP and BCP+DHA groups (Figure 6).


In vitro and in vivo characterization of the new analgesic combination Beta-caryophyllene and docosahexaenoic Acid.

Fiorenzani P, Lamponi S, Magnani A, Ceccarelli I, Aloisi AM - Evid Based Complement Alternat Med (2014)

Analgesimeter test: histogram of the % variation of latency of paw-withdrawal recorded in analgesimeter tests 2 (a) and 3 (b) with respect to the mean latency recorded during the first test, in the right and left paw in animals treated with OIL (white), BCP (light gray), and BCP+DHA (dark gray). Values are means ± SEM. *P < 0.01 versus BCP.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4109702&req=5

fig6: Analgesimeter test: histogram of the % variation of latency of paw-withdrawal recorded in analgesimeter tests 2 (a) and 3 (b) with respect to the mean latency recorded during the first test, in the right and left paw in animals treated with OIL (white), BCP (light gray), and BCP+DHA (dark gray). Values are means ± SEM. *P < 0.01 versus BCP.
Mentions: This test was carried out to evaluate the effect of one and two weeks of BCP and BCP+DHA treatment on the mechanical paw-withdrawal threshold with respect to basal conditions (Analg 1). One-way ANOVA applied to the percentage of variation of latency recorded during the second and third tests with respect to the first one revealed different effects of the treatments, while BCP alone always resulted in higher values, that is, analgesia, BCP+DHA tended to produce lower (hyperalgesic) levels. In particular, there was a significant effect of treatment during the second test (Analg 2) for the right (treated) paw (F2,17 = 4.25; P < 0.03) due to the significant difference between the BCP and BCP+DHA groups (Figure 6).

Bottom Line: BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration.In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment.In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Surgery and Neuroscience, University of Siena, Via Aldo Moro, 53100 Siena, Italy.

ABSTRACT
Beta-caryophyllene (BCP) and docosahexaenoic acid (DHA) are components of several plants with documented anti-inflammatory and analgesic effects in animal pain models. In the present study, in vitro and in vivo tests were carried out to evaluate their effects, alone or in combination, during long-lasting administration in a model of persistent pain. IR spectra of the two compounds were obtained to determine their chemical stability and then in vitro toxicity was evaluated in fibroblasts and astrocytes. In the in vivo tests, the analgesic effects of BCP and BCP+DHA were determined in male rats subjected to a model of persistent recurrent pain (three repetitions of the formalin test once a week) to mimic recurrent pain. Both substances were administered per os in almond oil for 2 weeks. Gonadal hormones were determined at the end of the tests to evaluate treatment-induced effects on their levels. BCP changed fibroblast and astrocyte survival in a dose-dependent manner and the effect was counteracted by DHA coadministration. In the in vivo tests, pain responses were significantly decreased in the BCP and BCP+DHA groups with respect to OIL after 1 and 2 weeks of treatment. Estradiol and testosterone levels were increased only in the BCP group. In conclusion, BCP alone or at lower concentration in combination with DHA was efficacious in modulating pain, showing a clear analgesic activity.

No MeSH data available.


Related in: MedlinePlus